These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 3213521)

  • 1. [Study on the polymorphic transition of semisynthetic triglycerides of fatty acid suppository bases].
    Xie XH; Gu XC; Liu FY
    Yao Xue Xue Bao; 1988 May; 23(5):388-93. PubMed ID: 3213521
    [No Abstract]   [Full Text] [Related]  

  • 2. Physical stability of semisynthetic suppository bases.
    Coben LJ; Lordi NG
    J Pharm Sci; 1980 Aug; 69(8):955-60. PubMed ID: 7400945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on stability of drugs in lyophilized suppository bases. 1. Separation and detection of products of decomposition of cyclovegantine, ethionamide and euphylline by means of thin-layer chromatography].
    Cieszyński T
    Acta Pol Pharm; 1971; 28(1):59-69. PubMed ID: 5577813
    [No Abstract]   [Full Text] [Related]  

  • 4. [Physical stability of suppository bases at different temperatures].
    Leszczyńska-Bakal H
    Acta Pol Pharm; 1971; 28(5):531-5. PubMed ID: 5145101
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymorphic transition rate of semisynthetic fatty suppository bases.
    Yoshino H; Kobayashi M; Samejima M
    Chem Pharm Bull (Tokyo); 1981 Sep; 29(9):2661-9. PubMed ID: 7349284
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of fatty acid composition on the properties and polymorphic transition of fatty suppository bases.
    Yoshino H; Kobayashi M; Samejima M
    Chem Pharm Bull (Tokyo); 1983 Jan; 31(1):237-46. PubMed ID: 6850937
    [No Abstract]   [Full Text] [Related]  

  • 7. [Choice of bases for suppositories with antibiotics. I. Stability of antibiotics in suppository bases].
    Zaremba A; Krówczyński L
    Acta Pol Pharm; 1974; 31(6):769-73. PubMed ID: 4447038
    [No Abstract]   [Full Text] [Related]  

  • 8. [Stability of drugs in lyophilic suppository bases. IV. Identification of decomposition products of cyclovegantine isolated from suppositories].
    Cieszyński T
    Acta Pol Pharm; 1974; 31(1):99-107. PubMed ID: 4151652
    [No Abstract]   [Full Text] [Related]  

  • 9. Study on stability of drugs in lyophilic suppository bases. 3. Isolation of cyclovegantine, ethionamide and euphyllin degradation products from suppositories.
    Cieszyński T
    Acta Pol Pharm; 1972; 29(1):75-83. PubMed ID: 5055291
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies on the stability of drugs in lyophilic suppository media. II. Evaluation of decay of cyclovegantine, ethionamide and euphylline in suppositories].
    Cieszyński T
    Acta Pol Pharm; 1971; 28(4):375-84. PubMed ID: 5145789
    [No Abstract]   [Full Text] [Related]  

  • 11. [Stability of drugs in lyophilic suppository bases. V. Identification of products of ethionamide decay isolated from suppositories].
    Cieszyński T
    Acta Pol Pharm; 1974; 31(5):651-6. PubMed ID: 4447018
    [No Abstract]   [Full Text] [Related]  

  • 12. [Studies of consistency in lipophilic bases of suppositories and of drug-containing suppositories. 1. Elasticity measurements].
    Regdon G; Mezey G; Sztankovánszky K
    Pharmazie; 1973 Jul; 28(7):461-4. PubMed ID: 4767495
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of suppository bases on the release properties of a potent antimicrobial agent (C31G).
    Caliş S; Sumnu M; Hincal AA
    Pharmazie; 1994 May; 49(5):336-9. PubMed ID: 8016179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of thermal constraints on the liberation of the active principal from the suppository form: the case of acetylsalicylic acid].
    Lasserre Y; Peneva B; Jacob M; Puech A
    J Pharm Belg; 1986; 41(1):12-6. PubMed ID: 3701563
    [No Abstract]   [Full Text] [Related]  

  • 15. [Applicability of densitometry procedures to the study of polymorphic transformation of triglyceride suppository size].
    Hüttenrauch R; Möller U
    Pharmazie; 1985 Aug; 40(8):582-3. PubMed ID: 4080812
    [No Abstract]   [Full Text] [Related]  

  • 16. [Kinetics of drug degradation. VI. Kinetics of degradation of phenylbutazone (FB) in suppository bases].
    Pawelczyk E; Zajac M
    Acta Pol Pharm; 1970; 27(2):113-7. PubMed ID: 5422244
    [No Abstract]   [Full Text] [Related]  

  • 17. Decomposition of aminophylline in suppository formulations.
    Brower JF; Juenge EC; Page DP; Dow ML
    J Pharm Sci; 1980 Aug; 69(8):942-5. PubMed ID: 7400941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preformulation experiences and in vitro model studies with spironolactone-containing suppositories.
    Regdon G; Deák D; Regdon G; Muskó Z; Erös I
    Pharmazie; 2001 Jan; 56(1):70-3. PubMed ID: 11213791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the liquid phase coexisting in fatty suppository bases on the polymorphic transition rate.
    Yoshino H; Kobayashi M; Samejima M
    Chem Pharm Bull (Tokyo); 1982 Aug; 30(8):2941-50. PubMed ID: 7139836
    [No Abstract]   [Full Text] [Related]  

  • 20. [Suppository preparation using polymeric forms].
    Chirkov AI; Lebedeva VV
    Voen Med Zh; 1980 Mar; (3):59-60. PubMed ID: 7368609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.